Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigen
AssigneesUniversity of Washington, Abacus Bioscience, Inc.
InventorsEdward A. Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
Claims10
A method for treating or limiting the development of a hepatitis-B virus (HBV)-related disorder, comprising administering to an individual in need thereof an amount effective to treat or limit development of the HBV-related disorder of a composition comprising a polypeptide, wherein the polypeptide comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3 residues 1-418.
Dependencies are inferred from the claim text.